Biotech

All Articles

FDA areas Kezar lupus trial in hold observing 4 client deaths

.The FDA has put Kezar Life Sciences' lupus trial on hold after the biotech hailed 4 fatalities in t...

Phase 3 Historian Stone trial strikes SMA target, sending out stock up 200%

.A stage 3 test of Academic Rock's back muscular degeneration (SMA) candidate has actually reached i...

CAMP 4 is most recent to eye IPO, while Upstream point out $182M planning

.RNA biotech CAMP4 Therapies has defined plans for a $67 thousand IPO, with inflammation-focused Ups...

Galecto purchases leukemia medication, loses bone tissue cancer resource in pivot

.A year after the failure of an idiopathic lung fibrosis candidate sent out Galecto on a hunt for re...

Judo tosses down $100M to knock senseless kidney health condition

.Taking the floor covering is Judo Bio, an up-and-coming biotech armed with $100 thousand to create ...

AstraZeneca pays out CSPC $100M for preclinical heart disease medication

.AstraZeneca has paid off CSPC Pharmaceutical Team $100 thousand for a preclinical cardiovascular di...

Zephyrm looks for Hong Kong IPO to fund stage 3 tissue treatment trials

.Zephyrm Bioscience is actually gusting towards the Hong Kong stock exchange, filing (PDF) for an IP...

Frazier Lifestyle Sciences gets $630M for small, mid-cap biotechs

.Frazier Lifespan Sciences has sourced an even more $630 thousand for its own fund concentrated on t...

GigaGen gathers as much as $135M BARDA bucks to hammer botox

.Antibody fan GigaGen, a subsidiary of Spanish biopharma Grifols, is ramping up its technology to ad...

GPCR organization Septerna declare IPO on stamina of preclinical information

.Septerna will figure out how a biotech without "any type of purposeful medical information" meals i...